Joint telehealth development to assist in diagnosing respiratory disease

Joint telehealth development to assist in diagnosing respiratory disease

Two digital health companies have joined forces to expand access to telehealth services targeted specifically at diagnosing respiratory diseases.

ResApp Health (ASX: RAP) will integrate its acute respiratory diagnostic test ResAppDx-EU into Phenix Health's telehealth smartphone app.

The partnership is a significant step toward accelerating diagnosis and treatment of respiratory diseases considering users of Phenix Health's app no longer have to rely on additional hardware; diagnosis can occur entirely within a single telehealth session.

By using machine learning algorithms, ResAppDx-EU analyses patients' cough sounds to diagnose lower respiratory tract diseases such as pneumonia and asthma exacerbations.

Ultimately, the partnership will enable doctors to determine whether a patient should attend a hospital or clinic for additional care, thus conserving already strained healthcare resources.

With people around the world encouraged to remain at home as much as possible telehealth technology is becoming a vital tool to help slow the spread of the novel coronavirus, enabling sick patients to see a doctor at a distance, away from those most vulnerable in the broader community.


Global Health answers call for virtual GP sessions


According to CEO and founder of Phenix Health Dr Gillian Alexis the company's app is well positioned to provide a valuable service to the Australian community.

"Phenix provides video consultations to patients across Australia and, since the beginning of this crisis, we have seen a 30 per cent month-on-month increase in the number of consultations," says Alexis.

"Our virtual clinic can be accessed nationwide through HealthEngine or directly via our downloadable app, and for patients told to self-isolate for possible COVID-19, these consultations are reimbursable under the MBS scheme."

"Phenix knows that implementing a telehealth service for patients must go beyond the limits of consumer video chat platforms like Skype which is why we are working with ResApp to bring their advanced diagnostic tool to our platform."

Shares in ResApp are up 117.39 per cent to $0.15 per share at 3:11PM AEDT.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Advertisement

Related Stories

Australia's Top 50 fastest growing tech companies revealed

Australia's Top 50 fastest growing tech companies revealed

The Deloitte Technology Fast 50 Australia awards this year have h...

Lendlease CFO Tarun Gupta steps down for top job at Stockland

Lendlease CFO Tarun Gupta steps down for top job at Stockland

The CFO of listed property group Lendlease (ASX: LLC) Tarun Gupta...

Craig Gore jailed for two years over super fund scam

Craig Gore jailed for two years over super fund scam

Craig Gore (pictured), a former high-flying rich lister who crash...

Bega buying back the farm with $534m deal for Lion Dairy

Bega buying back the farm with $534m deal for Lion Dairy

Bega Cheese (ASX: BGA) will acquire Kirin-owned Lion Dairy & ...